ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1894

Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System

Gregory McDermott1, Mark Hammer2, Xiaosong Wang3, Misti Paudel4, Sung Hae Chang5, Pierre-Antoine Juge6, Qianru Zhang7, Jessica Lorusso8, Amie Samulyov8, Kathleen Vanni2, Alene Saavedra2, Emily Kowalski2, Grace Qian3, Katarina Bade2, Kevin Mueller2, Jeffrey Sparks9 and Suzanne Byrne2, 1Brigham and Women's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, 6Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 7Harard Medical School, Cambridge, 8Mass General Brigham, Boston, MA, 9Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

Meeting: ACR Convergence 2024

Keywords: interstitial lung disease, Oncology, pulmonary, rheumatoid arthritis, Smoking

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Cigarette smoking is a risk factor for both lung cancer and RA. Furthermore, RA is associated with pulmonary abnormalities including interstitial lung disease, bronchiectasis, and rheumatoid lung nodules. In 2013, the US Preventative Services Task Force recommended lung cancer screening with low-dose chest computed tomography (CT) for asymptomatic adults aged 55-80 who are current or former smokers (quit within 15 years) with ³20 pack-years of smoking history. We hypothesized that RA would be associated with increased abnormal findings on low-dose CT chest imaging, including pulmonary nodules, fibrotic lung changes, bronchiectasis, and lung cancer.

Methods: We identified all patients screened for lung cancer with indicated low-dose CT chest imaging between 2015 and 2023 at a large multi-hospital system. Among this cohort, we used administrative codes and an electronic health records (EHR)-based algorithm to identify RA cases and confirmed RA diagnosis, date of diagnosis, and serostatus for all patients by medical record review. Non-RA comparators had no RA codes. A “positive screen” on the low-dose chest CT was defined as lung nodules requiring follow-up or biopsy. Fibrotic lung changes were defined as thoracic radiologist documentation of interstitial lung changes, interstitial fibrosis, pulmonary fibrosis, reticular changes, reticulation, honeycombing, or bronchiolectasis on radiology report. Bronchiectasis presence was determined by thoracic radiologist documentation. Sex, smoking status, pack-years, and lung cancer presence detected after low-dose chest CT were determined by EHR review. We examined associations between RA and abnormal findings on low-dose chest CT using multivariable logistic regression adjusted for age, sex, smoking status, and pack-years.

Results: Among 15,033 patients who underwent indicated low-dose CT chest imaging for lung cancer screening, we identified 228 RA cases (mean age 64 years, 72% female, 71% seropositive, mean RA duration 9 years) and 14,805 non-RA comparators (Table 1). A total of 26.8% of RA cases vs. 22.2% of non-RA had a “positive screen” that required follow-up or biopsy; 4.8% of RA cases vs. 3.6% of non-RA were diagnosed with lung cancer, though neither were statistically different. Fibrotic lung changes (7.9% vs 5.1%, p=0.06) and bronchiectasis (15.4% vs. 11.0%, p=0.04) were more prevalent in RA vs. non-RA comparators (Table 2). In multivariable models, RA was associated with fibrotic changes (OR 1.66 95%CI 1.02-2.72) and bronchiectasis (OR 1.66 95%CI 1.00-2.08) (Table 3). The associations were strongest for seropositive RA vs. non-RA (OR for fibrosis 2.33, 95%CI 1.37-3.95; OR for bronchiectasis 1.54, 95%CI 0.99-2.38).

Conclusion: In usual clinical care, patients with RA had a high prevalence of pulmonary abnormalities detected by low-dose chest CT performed for lung cancer screening. Patients with RA were more likely to have fibrotic changes and bronchiectasis compared to non-RA controls. About 1 in 4 smokers with RA had a positive screen, while 1 in 20 had lung cancer. These controlled results of screening with low-dose chest CT imaging may inform ongoing efforts on RA-ILD screening strategies.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. McDermott: None; M. Hammer: None; X. Wang: None; M. Paudel: UnitedHealth Group, 11; S. Chang: None; P. Juge: Nordic, 6; Q. Zhang: None; J. Lorusso: None; A. Samulyov: None; K. Vanni: None; A. Saavedra: None; E. Kowalski: None; G. Qian: None; K. Bade: None; K. Mueller: None; J. Sparks: Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Gilead, 2, Janssen, 2, Pfizer, 2, UCB, 2; S. Byrne: None.

To cite this abstract in AMA style:

McDermott G, Hammer M, Wang X, Paudel M, Chang S, Juge P, Zhang Q, Lorusso J, Samulyov A, Vanni K, Saavedra A, Kowalski E, Qian G, Bade K, Mueller K, Sparks J, Byrne S. Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/detection-of-fibrotic-lung-changes-and-bronchiectasis-in-ra-patients-screened-for-lung-cancer-with-low-dose-ct-chest-results-from-a-large-multi-hospital-system/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detection-of-fibrotic-lung-changes-and-bronchiectasis-in-ra-patients-screened-for-lung-cancer-with-low-dose-ct-chest-results-from-a-large-multi-hospital-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology